A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 242 participants.
Also called NCT05901831
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 242 participants
- Sponsor
- Registry
-
NCT05901831 -
2022-503024-27-00
-
- Other papers using this trial's data
- Finerenone in Type 1 Diabetes and Chronic Kidney Disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, China, Denmark, Germany, Italy, South Korea, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05901831. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-26 (actual); primary completion 2025-08-20 (actual). Results posted on 2026-10-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
- Acronym
- FINE-ONE
- Condition
- Chronic Kidney Disease
- Condition
- Type 1 Diabetes Mellitus
- Intervention (Drug)
- Finerenone
- Intervention (Other)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct05901831- Content hash
d7fd286f4411d74fba1490ec13002569a63a21c98f7a054d67a9db29cda04588